Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) EBITDA (2016 - 2025)

Historic EBITDA for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to -$5.1 million.

  • Abeona Therapeutics' EBITDA rose 8310.33% to -$5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.4 million, marking a year-over-year increase of 21609.05%. This contributed to the annual value of -$63.7 million for FY2024, which is 1761.66% down from last year.
  • Abeona Therapeutics' EBITDA amounted to -$5.1 million in Q3 2025, which was up 8310.33% from $108.9 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' EBITDA peaked at $108.9 million during Q2 2025, and registered a low of -$46.7 million during Q4 2021.
  • Moreover, its 5-year median value for EBITDA was -$11.8 million (2023), whereas its average is -$8.1 million.
  • Per our database at Business Quant, Abeona Therapeutics' EBITDA plummeted by 25050.32% in 2024 and then surged by 135996.51% in 2025.
  • Abeona Therapeutics' EBITDA (Quarter) stood at -$46.7 million in 2021, then skyrocketed by 84.57% to -$7.2 million in 2022, then tumbled by 129.78% to -$16.6 million in 2023, then skyrocketed by 44.43% to -$9.2 million in 2024, then surged by 44.51% to -$5.1 million in 2025.
  • Its EBITDA stands at -$5.1 million for Q3 2025, versus $108.9 million for Q2 2025 and -$12.1 million for Q1 2025.